Cardiology

List of Cardiology Clinical Trials:

  • A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When AMG-145 is Used in Combination with Statin Therapy in Patients with Clinically Evident Cardiovascular Disease

Sponsor: Amgen

Protocol Number: 20110118 (FOURIER)

 

  • A Randomized, Multi-Center, Placebo-Controlled, Parallel Group Study to Determine the Effects of Amg-145 Treatment on Atherosclerotic Disease Burden as Measured by Intravascular Ultrasound in Patients Undergoing Coronary Catherization

Sponsor: Amgen

Protocol Number: 20120153 (GLAGOV)

 

  • A multicenter, Open Label Extension (OLE) Study to Assess the Long-term Safety and Efficay of Evolocumab

Sponsor: Amgen

Protocol Number: 20140128

 

  • A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of JNJ-28431754 on Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes Mellitus

Sponsor: Janssen Cilag

Protocol Number: 28431754DIA3008 (CANVAS)

 

  • A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effect of Canagliflozin on Renal Endpoint in Adult subjects with Type 2 Diabetes Mellitus.

Sponsor: Janssen Cilag

Protocol Number: 28431754DIA4003 (CANVAS-R)

 

  • Xarelto on prevention of stroke and non- central nervous system systemic embolism in patients with non-valvular atrial fibrillation in Asia (A non-interventional study).

Sponsor: Bayer

Protocol Number: XA1205 (XANAP)

 

  • An Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Oral Rivaroxaban with Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects with Chronic Heart Failure and Significant Coronary Artery Disease Following a Hospitalization for Exacerbaation of Heart Failure.

Sponsor: Janssen Cilag

Protocol Number: RIVAROXHFA3001

 

  • An Open-Label, Randomized, Controlled, Multicenter Study Exploring Two Exploring Two Treatment Strateries of Rivaroxaban And A Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention.

Sponsor: Janssen Cilag

Protocol Number: RIVAROXAFL3003